Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
Niraparib is used as first-line maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is also used as maintenance treatment in patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This medicine is used in patients who have had received platinum-based cancer medicines.
Niraparib is also used to treat advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients who have received 3 or more cancer treatment regimens, and with tumors that are caused by a certain “BRCA” gene mutation, or a positive laboratory test, and whose cancer was in response to treatment with platinum-based cancer medicines, and who have progressed more than 6 months after the last treatment.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
From Mayo Clinic to your inbox
Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health.
ErrorEmail field is required
ErrorInclude a valid email address
To provide you with the most relevant and helpful information, and understand which
information is beneficial, we may combine your email and website usage information with
other information we have about you. If you are a Mayo Clinic patient, this could
include protected health information. If we combine this information with your protected
health information, we will treat all of that information as protected health
information and will only use or disclose that information as set forth in our notice of
privacy practices. You may opt-out of email communications at any time by clicking on
the unsubscribe link in the e-mail.
Thank you for subscribing
Our Housecall e-newsletter will keep you up-to-date on the latest health information.
Sorry something went wrong with your subscription
Please, try again in a couple of minutes